Ann: Half Year Results Presentation - 30 June 2024, page-3

I dunno...what you say is correct . I do not think there is anything wrong here but it appears to me that a few things have happened from the initial plan some years ago.
Firstly, the oncology and other human testing has turned out very much more difficult than was originally expected. Medical applications, even when shown to work, are difficult and take sometimes years to get past the FDA. Neither of the above are ready yet for serious trials.
Secondly, Sales are growing slowly but I for one was not aware that PetTkr already had a competitor in the market. I had been of the impression it was a whole new thing.
Thirdly, Sentia has been nowhere near the success I had hoped it may be. Seems uptake is very much less than I had expected.
I think they have a long journey ahead of them to get anywhere near critical mass. I have moved my investment in UBI some little while ago. I was just reading their Half Year report as I do with lot's of investments that have passed my way over the years.
There will be no Boom in sales.If they can keep their head above water then somewhere down the track they can be cashflow positive and maybe profitable. I hope they do but they have broken lot's of timeline promises.